06855.HK
Ascentage Pharma Group International
HKSE · Healthcare · Biotechnology · CN
HKD 35.00
+1.74%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 559.3M | 980.6M | 222.0M | 209.7M |
| Cost of Revenue | 152.4M | 131.9M | 29.1M | 30.5M | 22.0M |
| Gross Profit | 871.0M | 427.3M | 951.6M | 191.4M | 187.7M |
| Operating Expenses | |||||
| R&D Expense | 2.3B | 1.1B | 947.2M | 707.0M | 743.1M |
| SG&A Expense | 1.1B | 523.4M | 383.1M | 376.5M | 328.0M |
| General & Admin Expense | 199.8M | — | 187.1M | 181.1M | 170.5M |
| Selling & Marketing Expense | 244.1M | — | 196.0M | 195.4M | 157.4M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 3.4B | 1.6B | 1.3B | 1.1B | 1.1B |
| Cost and Expenses | 3.5B | 1.7B | 1.4B | 1.1B | 1.1B |
| Operating Income (EBIT) | (2.5B) | (1.2B) | (378.8M) | (892.0M) | (883.4M) |
| Non-Operating | |||||
| Interest Income | 90.4M | 80.0M | 37.8M | 32.4M | 9.7M |
| Interest Expense | 52.3M | 52.7M | 64.5M | 96.1M | 52.8M |
| Net Interest Income | 38.1M | 27.3M | (26.6M) | (63.6M) | (43.1M) |
| Other Non-Op Income/Expense | (71.0M) | (23.2M) | (16.5M) | (40.9M) | (3.8M) |
| Non-Operating Income (excl Interest) | — | — | (38.9M) | (55.2M) | — |
| EBT (Pre-Tax Income) | (2.6B) | (1.2B) | (395.3M) | (932.9M) | (887.2M) |
| Income Tax Expense | 30.7M | 6.8M | 10.4M | (7.2M) | (4.2M) |
| Bottom Line | |||||
| Net Income | (2.6B) | (1.2B) | (405.4M) | (925.6M) | (882.9M) |
| Earnings from Cont. Ops | (2.6B) | (1.2B) | (405.7M) | (925.7M) | (882.9M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (2.6B) | (1.2B) | (405.4M) | (925.6M) | (882.9M) |
| Per Share | |||||
| Basic EPS | (HK$7.44) | (HK$3.40) | (HK$1.34) | (HK$3.28) | (HK$3.35) |
| Diluted EPS | (HK$7.44) | (HK$3.40) | (HK$1.34) | (HK$3.28) | (HK$3.35) |
| Revenue Per Share | HK$2.74 | HK$1.57 | HK$3.25 | HK$0.79 | HK$0.80 |
| Shares | |||||
| Basic Shares Outstanding | 373.2M | 356.1M | 302.1M | 282.3M | 263.7M |
| Diluted Shares Outstanding | 373.2M | 356.1M | 302.1M | 282.3M | 263.7M |
| Profitability Metrics | |||||
| EBITDA | (2.3B) | (1.1B) | (299.6M) | (743.6M) | (836.0M) |
| D&A | 160.6M | 84.2M | 79.2M | 93.2M | 47.4M |
| EBIT | (2.5B) | (1.2B) | (378.8M) | (836.8M) | (883.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026